Demographics and baseline characteristics of patients
| N | Total | GLP-1RA naïve | GLP-1RA switchers |
| 1212 | 960 | 252 | |
| Age, years | 60.1 (10.9) | 60.1 (11.1) | 60.0 (10.2) |
| Female, n (%) | 473 (39.0) | 362 (37.7) | 111 (44.0) |
| Race, n (%) | |||
| White | 1103 (91.0) | 867 (90.3) | 236 (93.7) |
| Asian | 61 (5.0) | 53 (5.5) | 8 (3.2) |
| Black or African-American | 22 (1.8) | 18 (1.9) | 4 (1.6) |
| Other | 26 (2.1) | 22 (2.3) | 4 (1.6) |
| Baseline HbA1c, % | 8.1 (1.5) | 8.2 (1.5) | 7.8 (1.2) |
| Baseline HbA1c <7.0%, n (%) | 231 (19.1) | 172 (17.9) | 59 (23.4) |
| Fasting plasma glucose, mmol/L* | 9.2 (3.2) | 9.4 (3.2) | 8.7 (3.2) |
| Body weight, kg† | 101.5 (21.0) | 101.2 (21.0) | 102.4 (20.7) |
| BMI, kg/m2‡ | 34.9 (6.6) | 34.7 (6.6) | 35.5 (6.6) |
| Diabetes duration, years§ | 12.2 (7.8) | 11.8 (7.8) | 13.7 (7.6) |
| eGFR, mL/min/1.73 m2¶ | 84.4 (21.6) | 84.5 (21.9) | 84.3 (20.7) |
| Diabetic complications, n (%) | |||
| Diabetic retinopathy** | 210 (17.4) | 170 (17.7) | 40 (15.9) |
| Diabetic neuropathy†† | 200 (16.5) | 169 (17.6) | 31 (12.3) |
| Diabetic nephropathy | 184 (15.2) | 137 (14.3) | 47 (18.7) |
| Comorbidities, n (%) | |||
| Dyslipidemia | 754 (62.2) | 585 (60.9) | 169 (67.1) |
| Hypertension | 846 (69.8) | 658 (68.5) | 188 (74.6) |
| Coronary heart disease | 197 (16.3) | 152 (15.8) | 45 (17.9) |
| Stroke | 36 (3.0) | 28 (2.9) | 8 (3.2) |
| Heart failure | 35 (2.9) | 30 (3.1) | 5 (2.0) |
| Peripheral vascular disease | 26 (2.1) | 19 (2.0) | 7 (2.8) |
| Prescribed starting dose of semaglutide, n (%) | |||
| <0.25 mg | 2 (0.2) | 2 (0.2) | 0 |
| 0.25 mg | 937 (77.3) | 808 (84.2) | 129 (51.2) |
| 0.5 mg | 191 (15.8) | 99 (10.3) | 92 (36.5) |
| 1.0 mg | 82 (6.8) | 51 (5.3) | 31 (12.3) |
| Reasons for initiating semaglutide treatment, n (%)‡‡ | |||
| Improve glycemic control | 1020 (84.2) | 819 (85.3) | 201 (79.8) |
| Weight reduction | 916 (75.6) | 720 (75.0) | 196 (77.8) |
| Issues with hypoglycemia on current treatment | 57 (4.7) | 53 (5.5) | 4 (1.6) |
| Address cardiovascular risk factors | 300 (24.8) | 236 (24.6) | 64 (25.4) |
| Simplify current treatment regimen | 337 (27.8) | 243 (25.3) | 94 (37.3) |
| Convenience | 235 (19.4) | 166 (17.3) | 69 (27.4) |
| Other | 44 (3.6) | 32 (3.3) | 12 (4.8) |
| Missing | 1 (0.1) | 1 (0.1) | 0 |
Demographic data for other patient subgroups are included in the supplement.
N=1212 for overall population, N=960 for GLP-1RA-naïve patients and N=252 for GLP-1RA switchers unless otherwise indicated.
*n=574, n=435 and n=139.
†n=1201, n=951 and n=250.
‡n=1195, n=945 and n=250.
§n=1210, n=959 and n=251.
¶n=913, n=726, and n=187.
**n=1101, n=959 and n=251.
††n=1210, n=958 and n=252.
‡‡More than one reason could be selected for initiating semaglutide. Data, which are from the full analysis set, are mean (SD) or number (proportion) of patients.
BMI, body mass index; eGFR, estimated glomerular filtration rate; GLP-1RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated hemoglobin; SD, standard deviation.